Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1821-1840 of 2,120 trials

Breast Cancer Diagnosis: Contrast-Enhanced Spectral Mammography

We are evaluating a new imaging method to see if it improves the accuracy of breast cancer diagnosis. This may help reduce the number of unnecessary biopsies for suspicious lesions.

Breast Lesions6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncologyOtolaryngology

Duchenne Muscular Dystrophy: ENTR-601-45 Treatment Study

We are evaluating a new treatment for Duchenne muscular dystrophy to see if it is safe and well-tolerated. This study will help us understand how the treatment works in the body.

Duchenne Muscular Dystrophy6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Grass Pollen Allergy: CLU-RX-PHL Treatment

We are testing a new subcutaneous treatment for people with grass pollen allergy. The study aims to find the most effective and safest dose to help manage allergy symptoms.

Allergic Rhinitis Due to Pollen6-12 monthsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesAllergologyInternal Medicine

Chronic Inflammatory Demyelinating Polyneuropathy: DNTH103 Treatment Study

We are studying a new treatment called DNTH103 for adults with Chronic Inflammatory Demyelinating Polyneuropathy. The trial aims to see if it can help reduce relapses and improve overall health compared to a placebo.

Chronic Inflammatory Demyelinating Polyneuropathy>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Severe Asthma: Tezepelumab Treatment

We are exploring how Tezepelumab may improve airway barrier function in patients with severe asthma, including those with chronic rhinosinusitis. This study looks at the effects of the treatment on the airways' response to harmful substances.

Severe Asthma with Chronic Rhinosinusitis and Nasal PolypsSevere Asthma without Chronic Rhinosinusitis>2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesAllergologyOtolaryngologyPulmonology

Neovascular Age-Related Macular Degeneration: Faricimab Injections

We are studying the safety and long-term effectiveness of faricimab injections for people with neovascular age-related macular degeneration. The goal is to see if it improves vision and how well it works over time.

Neovascular Age-Related Macular Degeneration>2 yearsConfirmation phase (III)Monitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOphthalmology

Severe Asthma: Dupilumab Treatment Study

We are investigating how Dupilumab affects mucus buildup and immune responses in patients with severe asthma. This study aims to improve understanding of asthma management and treatment options.

Severe Asthma>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteAllergologyPulmonology

Kidney Transplant: Ravulizumab Study

We are testing Ravulizumab in adults at high risk of delayed graft function after kidney transplantation. The goal is to see if it helps improve kidney function and reduces the need for dialysis.

Delayed Graft Function after Kidney Transplantation1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteInternal MedicineNephrology

Anesthesia Study: Ketamine vs. Propofol Combinations

We are comparing the effectiveness of ketamine alone and a ketamine-propofol mix against standard propofol for safe tracheal intubation in patients at risk of aspiration during surgery. The goal is to see which option leads to fewer complications and better tolerance.

Rapid Sequence Induction≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPsychiatry

Duchenne Muscular Dystrophy: ENTR-601-44 Treatment Study

We are evaluating a new treatment for Duchenne muscular dystrophy to see if it is safe and how it affects muscle function. Participants will receive either the treatment or a placebo in a controlled setting.

Duchenne Muscular Dystrophy1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

Central Retinal Artery Occlusion: Tenecteplase Study

We are investigating whether tenecteplase can help improve vision in patients with central retinal artery occlusion when given shortly after symptoms begin. This study compares it to standard treatment to see which is more effective.

Central Retinal Artery Occlusion>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesCardiologyNeurologyOphthalmology

Surgery and Immune Response: Low-Dose Interferon-alfa2a Study

We are investigating whether low-dose Interferon-alfa2a can improve immune function and recovery in patients undergoing surgery. This study looks at immune cell changes and recovery quality compared to a placebo.

Colon Cancer1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Advanced Basal Cell Carcinoma: Cemiplimab Treatment Study

We are studying the effectiveness and safety of Cemiplimab for patients with advanced basal cell carcinoma. This trial aims to see how well it works as a first-line treatment and to identify factors that may affect treatment outcomes.

Basal Cell Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesDermatologyOncology

Prostate Cancer: Short vs. Long-Term Androgen Deprivation Therapy

We are comparing short-term and long-term hormone therapy combined with radiotherapy for men with prostate cancer that has returned after surgery. The goal is to see which approach may improve survival and reduce recurrence.

Prostate Cancer1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncologyUrology

Severe Spasticity: Botulinum Toxin Type A Treatment

We are studying the effects and safety of a personalized dose of botulinum toxin type A for individuals with severe spasticity. This trial aims to see how well it works for managing symptoms in the upper and lower limbs.

Spasticity Due to Brain Damage1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNeurology

Inhaled Sevoflurane for Sedation in Critically Ill Patients

We are studying whether inhaled sevoflurane improves breathing and safety in ICU patients at risk for ARDS compared to standard sedation methods. This research may help us understand better sedation options for these vulnerable patients.

Patients at Risk of Acute Respiratory Distress Syndrome>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPulmonology

Labor Induction: Oxytocin vs. Prostaglandins

We are studying whether oxytocin is as safe as prostaglandins for inducing labor in women with an unfavorable cervix. This trial will help us understand the risks and benefits of both methods.

Labor Induction>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesGynecology and Obstetrics

Metastatic Colorectal Cancer: Choosing Chemotherapy

We are exploring a new approach to select between two chemotherapy options for patients with metastatic colorectal cancer. This study will help us understand how well these treatments work and their potential side effects.

MSS/pMMR Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Endoscopic Sleeve Gastroplasty: Impact of Proton Pump Inhibitors

We are studying how proton pump inhibitors affect the success of endoscopic sleeve gastroplasty in people seeking weight loss. We also want to learn about their effects on quality of life and metabolic health.

Obesity1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Dexamethasone for Severe Burns

We are studying whether early treatment with dexamethasone can help reduce serious complications and death in patients with severe burns. This trial will also look at its effects on infections and recovery times.

Severe Burns3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineOrthopedics and Traumatology